Text Size
15 studies found for:    "Muckle-Wells syndrome"

Modify this search | How to Use Search Results

Show Display Options
Rank Status Study
1 Completed Safety and Tolerability of Rilonacept in Muckle-Wells Syndrome (MWS) or Schnitzler Syndrome (SchS)
Conditions: Muckle-Wells Syndrome;   Schnitzler Syndrome
Intervention: Drug: rilonacept
2 Completed
Has Results 		Efficacy, Safety, and Tolerability of ACZ885 in Patients With Muckle-Wells Syndrome
Condition: Muckle Wells Syndrome
Interventions: Drug: ACZ885;   Drug: Placebo
3 Withdrawn A Pilot Study of XOMA 052 in Familial Cold Autoinflammatory Syndrome / Muckle-Wells Syndrome and Behcet's Disease
Conditions: Muckle Wells Syndrome;   Autoinflammatory;   Behcet's Disease
Intervention: Drug: XOMA 052
4 Completed
Has Results 		Efficacy and Safety of ACZ885 in Patients With the Following Cryopyrin-associated Periodic Syndromes: Familial Cold Autoinflammatory Syndrome, Muckle-Wells Syndrome, or Neonatal Onset Multisystem Inflammatory Disease
Conditions: Cryopyrin-associated Periodic Syndromes:;   Familial Cold Autoinflammatory Syndrome;   Muckle Wells Syndrome;   Neonatal Onset Multisystem Inflammatory Disease
Intervention: Drug: Canakinumab (ACZ885)
5 Recruiting Efficacy, Safety and Tolerability of ACZ885 in Pediatric Patients With the Following Cryopyrin-associated Periodic Syndromes: Familial Cold Autoinflammatory Syndrome, Muckle-Wells Syndrome, or Neonatal Onset Multisystem Inflammatory Disease
Conditions: Cryopyrin-associated Periodic Syndromes;   Familial Cold Autoinflammatory Syndrome;   Muckle-Wells Syndrome;   Neonatal Onset Multisystem Inflammatory Disease
Intervention: Biological: ACZ885
6 Recruiting Efficacy, Safety and Tolerability of ACZ885 in Pediatric Patients With the Following Cryopyrin-associated Periodic Syndromes: Familial Cold Autoinflammatory Syndrome, Muckle-Wells Syndrome, or Neonatal Onset Multisystem Inflammatory Disease
Conditions: Cryopyrin-associated Periodic Syndromes;   Familial Cold Autoinflammatory Syndrome;   Muckle-Wells Syndrome;   Neonatal Onset Multisystem Inflammatory Disease
Intervention: Biological: ACZ885
7 Completed Efficacy and Safety Study of Canakinumab Administered for 6 Months (24 Weeks) in Japanese Patients With Cryopyrin-associated Periodic Syndromes Followed by an Extension Phase
Conditions: Cryopyrin-associated Periodic Syndromes;   Familial Cold Autoinflammatory Syndrome;   Muckle-Wells Syndrome;   Neonatal Onset Multisystem Inflammatory Disease
Intervention: Biological: canakinumab
8 Completed
Has Results 		Rilonacept for Treatment of Cryopyrin-Associated Periodic Syndromes (CAPS)
Conditions: Familial Cold Autoinflammatory Syndrome (FCAS);   Familial Cold Urticaria;   Muckle-Wells Syndrome (MWS);   Genetic Diseases, Inborn
Interventions: Drug: rilonacept 160 mg;   Drug: Placebo
9 Recruiting Continued Access to PREVAIL (CAP2)
Condition: Atrial Fibrillation
Intervention: Device: WATCHMAN LAA Closure Technology
10 Unknown † The CAP-2 Trial: Effect of Direct Pulp Capping Versus Partial Pulpotomy
Condition: Dental Pulp Exposure
Intervention: Procedure: Pulp capping and partial pulpotomy
11 Completed Safety, Efficacy, Pharmacokinetics, Pharmacodynamics of ACZ885 in Patients With NALP3 Mutations and Clinical Symptoms
Condition: NALP3 Mutation
Intervention: Drug: canakinumab
12 Recruiting Familial Mediterranean Fever and Related Disorders: Genetics and Disease Characteristics
Condition: Periodic Disease
Intervention:
13 Completed The Safety and Efficacy of Canakinumab in Patients Aged 4 Years or Older Diagnosed With Cryopyrin-associated Periodic Syndromes (CAPS) in Canada
Condition: Cryopyrin Associated Periodic Syndrome
Intervention: Drug: canakinumab (company code: ACZ885D)
14 Recruiting Clinical Outcomes and Safety: A Registry Study of Ilaris (Canakinumab) Patients
Conditions: Cryopyrin-associated Periodic Syndromes (CAPS);   Familial Cold Autoinflam Syn (FCAS);   Muckle-wells Syn (MWS);   Neonatal Onset Multisystem Inflam Disease (NOMID)
Intervention:
15 Completed Internleukin-1 Trap to Treat Autoinflammatory Disease
Conditions: Inflammation;   Familial Mediterranean Fever;   Still's Disease, Adult-Onset
Intervention: Drug: IL-1 Trap
To Top

† Indicates status has not been verified in more than two years